Cardiff Oncology (CRDF) Stock
Early stage biotech company developing cancer treatments. Here's the price, business snapshot, and what's worth knowing about Cardiff Oncology in October 2026.
Cardiff Oncology Inc (CRDF) is a small, clinical-stage biotechnology company focused on developing oncology treatments. With a market capitalisation around $148 million, it is early-stage and carries the higher risk profile typical of companies without commercial revenues. Investors should know Cardiff is research-driven: value depends heavily on clinical trial outcomes, regulatory progress and partnerships rather than current sales. News flow — trial readouts, investigator updates and licensing deals — can move the share price significantly. Financially, expect periodic funding needs through equity raises or collaborations, which can dilute existing holders. For those considering exposure, treat CRDF as a speculative, long-horizon position and weigh the potential upside from successful development against the significant chance of setbacks. This summary is educational only and not personal investment advice; consult a qualified adviser about suitability for your circumstances.
Cardiff Oncology (CRDF) Stock Forecast
Analyst price target, next 12 months
$8.81
+716.0% vs today's $1.08
Price range over the last 12 months
Close to its 12-month low
Analysts covering Cardiff Oncology have a consensus 12-month target of $8.81, above the current price of $1.08.
Analyst targets are opinions, not guarantees. Capital at risk. Data as of 25 May 2026.
Source: Analyst sentiment is provided by Refinitiv Ltd, a global leader in financial market data with over 40k business clients. Refinitiv Ltd is an independent third party to Nemo. This is not advice.
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Cardiff Oncology's stock with a target price of $8.81, indicating strong growth potential.
Financial Health
Cardiff Oncology is struggling with low revenue and is not generating enough cash flow.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
Catalysts to watch
Clinical readouts, regulatory updates and collaboration news can shift valuation quickly — though outcomes are uncertain and may increase volatility.
Development risk
As a research-led company, progress depends on trials and approvals; setbacks are common and can materially impact the share price.
Funding and partners
Partnerships or financing rounds can extend runway and validate programmes, but funding may dilute existing shareholders.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
